603077 和邦生物
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入6,813,6925.89%8,824,10813,038,9489,987,3545,260,766
减:营业总成本6,550,03624.50%7,325,6298,554,8506,435,6694,861,695
    其中:营业成本6,084,66624.52%6,771,5707,451,3155,854,7274,271,965
               财务费用32,109-552.50%(32,503)24,12684,400120,712
               资产减值损失(6,531)--(36,752)(80,828)--(5,979)
公允价值变动收益------------
投资收益(1,259)-102.73%75,21921,83126,95124,376
    其中:对联营企业和合营企业的投资收益(463)-101.02%51,22319,67012,8029,037
营业利润260,300-78.50%1,541,7924,481,1573,591,076440,493
利润总额259,501-78.55%1,535,9664,478,5623,578,38015,809
减:所得税费用63,964-67.33%257,266668,323551,87912,900
净利润195,537-80.72%1,278,6993,810,2393,026,5022,910
减:非控股权益(25,782)418.86%(4,545)3,4308,031(38,033)
股东净利润221,319-78.28%1,283,2443,806,8093,018,47140,942

市场价值指针
每股收益 (元) *0.027-77.05%0.1470.4380.3580.005
每股派息 (元) *0.020----0.0450.015--
每股净资产 (元) *2.125-5.13%2.2172.1651.6131.262
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容